Drug Administration to take the lead, the ex-factory price of drugs can be traced back across the country
The secret price of the ex-factory price of drugs will soon be lifted.
On March 20th, 2017, the reporter learned from the informed sources that the policy of information on the ex-factory price of pharmaceuticals that was brewed for one year is expected to be formally introduced before the end of June. According to previous plans, this mechanism will be led by the State Administration of Food and Drug Administration, cross-sector collaboration, the establishment of a unified cross-sector price information platform, the transparency of the factory drug prices from the individual provinces in Fujian, Jiangsu and other countries to push the country. On the same day, Wang Hesheng, deputy director of the National Health and Family Planning Commission, also emphasized that during the exclusive interview with Xinhua News Agency, this year China will carry out reforms to the whole process of drug production and circulation and squeeze the moisture of the high drug prices. The ex-factory price of pharmaceutical products can be traced back to establishment.
"Pocket" is no longer mysterious
In recent years, "remedy with medicine" has gradually evolved into a profit-seeking mechanism. The problems caused by such big prescriptions, infusions, and abuse of antibiotics as caused by medical institutions have become increasingly serious. As a result, patients have become increasingly unbearable. Since the launch of the new round of medical reform in 2009, the country has been eliminating drug additions as a breakthrough to break the "medicine-supplementing" mechanism. The data shows that through the reform, the proportion of public hospital medicines has dropped from 46% in 2009 to the current 40%.
As early as a year ago, the executive meeting of the State Council made it clear that we must speed up the establishment of traceability mechanisms for drug prices, promote the disclosure of drug price information, and make drug prices “transparent.” Three months later, the National Health and Family Planning Commission, the National Development and Reform Commission, and the State Food and Drug Administration and other 9 departments jointly issued the “Key Issues for Correcting Unhealthy Trends in Pharmaceutical Purchases and Marketing and Medical Services in 2016”, which was clearly established. The ex-factory price of pharmaceutical products can be traced back to the mechanism, promote the reform of pricing methods for medical services, strengthen the supervision of prices of drugs and high-value medical consumables that are not fully competitive in the market, and establish and improve the system for the monitoring and information release of drug prices.
By this year, the framework of the drug product price tracing mechanism has taken initial shape. In February, the General Office of the State Council issued the “Several Opinions on Further Reforming and Perfecting the Policies for the Production, Circulation and Use of Pharmaceuticals”. It is proposed that China should improve the drug price monitoring system and promote transparent pricing information in the pharmaceutical market. The food and drug supervision department took the lead in establishing a traceability mechanism for information on ex-factory price of pharmaceuticals, established a unified inter-departmental price information platform, and facilitated interconnection and interoperability with the centralized drug procurement platform (public resource transaction platform) and the Medicare payment audit platform, and strengthened related taxation. Sharing of data.
Mechanism framework surfaced
In industries where medicine is a very complex interest relationship, it is not easy to establish a clear and reliable ex-factory price tracing mechanism. Actually, as early as last year when the two National Conferences were held, Cui Hairong, member of the National Committee of the Chinese People's Political Consultative Conference and former deputy director of the National Bureau of Corruption Prevention, publicly disclosed the findings: "Although there are many kinds of drugs in China, there are only 500 kinds of drugs commonly used by the masses and the drug prices are high. The problem is very alarming.” He suggested that the customs declaration price be printed on imported medicine boxes. When domestically produced medicines are delivered, drug manufacturers will print the factory price on the medicine boxes. At the time, this proposal triggered an immediate social debate. At the same time, some experts also bluntly stated that this system is too difficult to implement and will be difficult to form in a short time.
"It is undeniable that printing the drug's factory price directly on the pillbox to the public will be a good practice for tracing back the ex-factory price of drugs." The experts in the medical field said that if this publicity method is adopted, it will not only bring drugs to pharmaceutical companies. The pressure is too great for them to dare to increase their prices rashly. At the same time, there will be evidence for the downstream links when negotiating drug prices.
Looking at the model of the entire traceability mechanism, the industry believes that as long as the tax invoice system is upgraded and the drug price traceability system is linked to the two-dimensional code of the invoice, it should be able to achieve the “one size-mindedness” function of the drug product price traceability system. Some experts even stated that under the background of the acceleration of reforms such as the reform of the camps and the “two-vote system” of drugs, if the monitoring platform links up with the traceability system for drug prices, there has been no obstacle to the relative transparency of drug prices, at least domestic pharmaceuticals. The company's production costs, profits, and expenses can all be financially calculated and audited.
Public information shows that at present, Jiangsu, Fujian and other places have begun to implement drug price traceability mechanisms, and these pioneering provinces have also been used as a reference sample for the establishment of a national system.
Ex-factory price monitoring
In this round of medical reforms, resolving the expensive medical problems brought about by the high price of medicine has always been the focus of reforms. On the morning of January 9, the official website of the National Health and Family Planning Commission disclosed the "Implementation Opinions (Trial Implementation) on Implementing the "Two-vote System" for Drug Purchase in Public Medical Institutions", requiring that public hospitals gradually implement "two The "ticket system" means that the pharmaceutical production enterprise should open an invoice for the circulation enterprise and the circulation enterprise should open an invoice for the medical institution.
Regarding this, Wang Zhaoping, a researcher at the Shanghai Jiaotong University Health Policy and Medical Management Institute, said that it is undeniable that the implementation of the “two-vote system” policy will, to a certain extent, curb the current phenomenon of high drug prices in China. It may also increase the concentration of companies in the pharmaceutical distribution industry, but at the same time, he worriedly stated that after eliminating the issue of fare increase in the circulation sector, China may face a sharp rise in the ex-factory price of pharmaceutical products, because the problem of using drugs to raise medical care has not been obtained. In the case of radical cure, only by raising the ex-factory price can there be sufficient profit margins for the hospitals and doctors to provide kickbacks. Therefore, only the elimination of this chaos is the ultimate solution to the false price of drugs.
“However, as a traceability mechanism for the ex-factory price of pharmaceuticals that has been highly hoped for by the public, in addition to the problems of multi-sector information sharing, system interconnection, etc., it is also necessary to resolve the current production costs of multinational pharmaceutical companies that are not producing drugs at home. Problems that cannot yet be fully collected." The above medical experts said.
Some analysts believe that if the pharmaceutical product price is marked on the medicine box, it will cause the public to cause the illusion that the same type of medicine price is cheaper and better. However, medicines are a special commodity. The quality of medicines cannot be judged by the level of price. If it is determined that such a system should be implemented, relevant departments must also develop more operative and reference price plans.